Table 2. Expression of potential targets for CAR-T cell therapy in MM.
| Target | Expression on MM cells (% of cases) | Expression on normal cells | References |
|---|---|---|---|
| Targets of clinical trials | |||
| CD138 | 90–100% | Plasma cells | (7,8) |
| CS1 | 95% | Plasma cells, T cells, NK cells, NK-T cells | (9,10) |
| CD38 | 80–100% | Monocytes, early B cells, activated T cells, NK cells | (11,12) |
| BCMA | 60–100% | Plasma cells, mature B cells | (13,14) |
| CD19 | Low expression, mostly on disease propagating cells | B cells | (15) |
| κ light chain | Expression on κ-restricted disease propagating cells | Mature B cells | (16) |
| Targets of preclinical experiments | |||
| CD56 | 60–80% | NK cells, NK-T cells | (17,18) |
| CD44v6 | 43% (in advanced stage) | Monocytes, activated T cells | (19) |
| Lewis Y | 52% | Plasma cells | (20) |
| NY-ESO-1 | 60% | (21) | |
| CD229 | 100% | T cells, B cells, plasma cells | (22) |
CAR, chimeric antigen receptor; MM, multiple myeloma.